Spravato is the most unique antidepressant you can take advantage
Spravato or esketamine has only been available to patients since 2019. The FDA has approved it not just for depression but treatment resistant patients, meaning for patient’s that have tried at least 2 or more medications.
If not Spravato, then what?
Unfortunately, the more antidepressant’s you try for depression without success, the less likely your going to respond overall. By the point a patient tries 3 antidepressant’s, the chance of remission rate is only about 15% with another treatment trial. Of the patient’s who remit (no longer clinically depressed) after 3 or 4 medication’s, there is a 60-70% chance they will relapse within 6 months – meaning their depression will return.
How effective is Spravato (Esketamine) augmentation?
There have been multiple phase 3 studies showing esketamine is effective for treatment resistant depression ( after trying 2 or more antidepressants). 65% of participants achieved a 50% or greater decrease in their depression, and another 32% of participants improved to the point they had no or mild symptoms.
Because Spravato was released in 2019 long term data is lacking up until recently. The most recent study, SUSTAIN-3 addressed the question of how endurable are these results. Does Spravato continue to be effective after 31.5 months or almost 3 years?
The response improved over time.
After 31.5 months the percentage of patients who remitted (no longer had significant clinical depression) increased from 35.6% and 46.1%. Esketamine is highly regulated under the REMS program, and no new safety issues were identified during long-term treatment (up to 4.5 years).
Spravato is Unique. Learn more about it
Not only is Spravato new, it can act rapidly. The expert’s at Libertas Mind specialize in Spravato therapy, but many in the mental health field aren’t as comfortable with this new medication. Because so many patient’s fall into the treatment resistant category, it’s imperative that not only providers are aware of this option, patient’s must be as well. If you or a loved one suffer’s from treatment resistant depression, please speak with your providers about Spravato as an option for treatment resistant depression.
If you or a loved one suffer's from treatment resistant depression, we do accept self referrals. Please speak with your provider's about Spravato as an option for treatment resistant depression.
